# Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

> **NCT05307198** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 38 (estimated)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** Oxaliplatin
- **PROCEDURE:** Rectectomy
- **DRUG:** Capecitabine
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05307198
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-11
- **Primary completion:** 2024-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307198, "Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05307198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*